G1
https://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-provides-update-phase-3-preserve-2-trial

Sarepta/DMD
https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-expanded-us-fda-approval-elevidys
https://www.sarepta.com/products-pipeline/products
https://www.pharmaceutical-technology.com/features/most-expensive-drugs-us/#:~:text=Developed%20by%20Sarepta%20Therapeutics%2C%20EXONDYS,drug%20inaccessible%20to%20many%20patients.
https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-vyondys-53tm
https://dss.mo.gov/mhd/cs/advisory/rdac/pdf/amondys-45-casimersen-ndfb_mo.pdf
https://www.fiercepharma.com/marketing/surprising-turn-fda-approves-sarepta-s-dmd-drug-it-just-shockingly-rejected#:~:text=Controversy%20erupted%20in%202016%20when,green%20light%20decided%20to%20retire.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154s000lbl.pdf
https://www.biospace.com/article/releases/ns-pharma-shares-preliminary-results-of-viltolarsen-ns-065-ncnp-01-phase-3-clinical-trial-racer53-study-/
https://www.fiercepharma.com/pharma/ns-pharmas-duchenne-therapy-viltepso-fails-confirmatory-trial#:~:text=Since%20NS%20Pharma%20launched%20its,(%24128%20million)%20this%20year.

Article referenced
https://www.statnews.com/2024/05/30/sarepta-therapeutics-ron-wong-biotech/

https://commons.wikimedia.org/wiki/File:SplicingSlide.png
